

# Teresa Allende Aydillo Gomez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8658314/publications.pdf>

Version: 2024-02-01

35  
papers

4,466  
citations

279487

23  
h-index

360668

35  
g-index

41  
all docs

41  
docs citations

41  
times ranked

10831  
citing authors

#	ARTICLE	IF	CITATIONS
1	A serological assay to detect SARS-CoV-2 seroconversion in humans. <i>Nature Medicine</i> , 2020, 26, 1033-1036.	15.2	1,678
2	SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28344-28354.	3.3	421
3	Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2586-2588.	13.9	356
4	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. <i>Nature Medicine</i> , 2021, 27, 106-114.	15.2	204
5	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. <i>Modern Pathology</i> , 2021, 34, 1456-1467.	2.9	184
6	Immunological imprinting of the antibody response in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 3781.	5.8	149
7	A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 67, 1322-1329.	2.9	145
8	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. <i>Cell Host and Microbe</i> , 2022, 30, 373-387.e7.	5.1	138
9	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021, 160, 2435-2450.e34.	0.6	118
10	Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1, a Randomized Controlled Clinical Trial. <i>Clinical Infectious Diseases</i> , 2017, 64, 829-838.	2.9	96
11	MHC class II proteins mediate cross-species entry of bat influenza viruses. <i>Nature</i> , 2019, 567, 109-112.	13.7	91
12	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. <i>Cell</i> , 2021, 184, 2618-2632.e17.	13.5	80
13	Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. <i>Clinical Microbiology and Infection</i> , 2012, 18, 67-73.	2.8	76
14	Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. <i>Journal of Infection</i> , 2012, 65, 423-430.	1.7	74
15	Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2205-2213.	2.6	45
16	Synthetically derived bat influenza A-like viruses reveal a cell type- but not species-specific tropism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12797-12802.	3.3	41
17	Limited extent and consequences of pancreatic SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110508.	2.9	36
18	Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1040.e11-1040.e18.	2.8	35

#	ARTICLE	IF	CITATIONS
19	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. <i>Human Pathology</i> , 2021, 114, 110-119.	1.1	32
20	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 547-556.	1.3	31
21	Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. <i>Clinical Microbiology and Infection</i> , 2012, 18, E533-E540.	2.8	29
22	Deficient Long-Term Response to Pandemic Vaccine Results in An Insufficient Antibody Response to Seasonal Influenza Vaccination in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2012, 93, 847-854.	0.5	27
23	Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo. <i>Frontiers in Microbiology</i> , 2019, 10, 2862.	1.5	27
24	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. <i>Journal of Infection</i> , 2013, 67, 185-193.	1.7	25
25	Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients. <i>Cell Reports Medicine</i> , 2020, 1, 100130.	3.3	18
26	Novel Bat Influenza Virus NS1 Proteins Bind Double-Stranded RNA and Antagonize Host Innate Immunity. <i>Journal of Virology</i> , 2015, 89, 10696-10701.	1.5	16
27	Effect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients. <i>Frontiers in Immunology</i> , 2020, 11, 1917.	2.2	16
28	Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent. <i>Kidney International</i> , 2020, 98, 782.	2.6	13
29	Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses. <i>Journal of Virology</i> , 2018, 92, .	1.5	11
30	Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2013, 17, 403-406.	0.5	9
31	Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial. <i>Trials</i> , 2014, 15, 338.	0.7	7
32	Humoral response to natural influenza infection in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2318-2328.	2.6	6
33	Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. <i>Vaccines</i> , 2020, 8, 666.	2.1	6
34	Obesity and Metabolic Dysregulation in Children Provide Protective Influenza Vaccine Responses. <i>Viruses</i> , 2022, 14, 124.	1.5	6
35	Protocol to isolate and assess spike protein cleavage in SARS-CoV-2 variants obtained from clinical COVID-19 samples. <i>STAR Protocols</i> , 2022, 3, 101502.	0.5	1